ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

NCT06513624 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

Interventions

DRUG: ETC-159
DRUG: Pembrolizumab
DRUG: Denosumab / Zoledronic Acid

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]